A Phase 1/2 clinical trial testing AXO-Lenti-PD (OXB102), Axovant‘s experimental gene therapy for Parkinson’s disease, has completed dosing of…
Articles by David Melamed, PhD
Vanderbilt University announced the opening of the Warren Center for Neuroscience Drug Discovery, promoting research into treatments for neurological…
Comparing the genomes of people with Parkinson’s disease to the specific genes expressed by cell types in the nervous…
Aspen Neuroscience has raised $70 million to advance the development of  Parkinson’s disease therapies using patients’ own cells.
An interdisciplinary team of researchers has developed a substance that may improve the differential diagnosis of Parkinson’s disease based…